Bedrijfsoverzicht
Jin Medical International Ltd. is primarily engaged in the design, development, manufacture, and sale of wheelchairs and other living aids tailored for individuals with disabilities, the elderly, and those recovering from injuries. The company operates within the Healthcare sector, specifically in the Medical Instruments & Supplies industry, positioning itself as a provider of essential mobility solutions and oxygen concealment equipment. Jin Medical International Ltd. currently maintains a market capitalization of $18.08M and reports annual revenue of $20.69M based on trailing twelve-month figures, while employing a workforce of 273 individuals. These valuation and revenue metrics indicate that the company functions as a micro-cap entity with a relatively modest operational scale compared to larger peers in the medical device sector. The combination of a small market cap and specific revenue generation suggests the business is in a niche segment where growth potential is tightly correlated with market penetration and product adoption rates within the disability support market.
Financiële gezondheid
The company recorded revenue of $20.69M for the trailing twelve months, generating a net income of $1.19M and an EBITDA of $851,585. The substantial gap between the total revenue of $20.69M and the net income of $1.19M reveals a significant cost structure burden, where operating expenses and taxes consume approximately 94.2% of top-line revenue before reaching the bottom line. However, the EBITDA figure of $851,585 provides a clearer view of operational cash generation before interest and taxes, highlighting the core profitability of the manufacturing and sales activities. Despite positive earnings, the free cash flow stands at $-5,111,959, which indicates that the company is burning cash, likely due to heavy capital expenditures or working capital requirements that exceed its operating cash inflows. This negative free cash flow suggests limited financial flexibility for immediate reinvestment without external financing. The company holds $29.63M in cash against $18.91M in debt, resulting in a net cash position that provides a buffer against its obligations. The debt-to-equity ratio is recorded at 63.95, a high figure that implies the balance sheet is leveraged, relying significantly on debt financing relative to shareholder equity. Nevertheless, the current ratio of 1.85 indicates that current assets are nearly double current liabilities, suggesting adequate short-term liquidity to meet upcoming financial obligations. Return on Equity is calculated at 4.8% and Return on Assets at 0.8%, metrics that reveal management effectiveness is currently constrained by the low asset turnover and the dilutive effect of the company's leverage structure on shareholder returns.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 11.55, while the forward P/E ratio is listed as N/A, implying that market analysts do not have a consensus on expected future earnings growth or that the forward earnings estimate is not yet available. The absence of a forward P/E suggests that the market may be pricing in uncertainty regarding future profitability rather than a specific growth trajectory. The price-to-book ratio stands at 0.61, indicating that the stock trades at a discount to its book value, which often suggests the market perceives the company's assets as undervalued or potentially impaired. The price-to-sales ratio is 0.87, and the EV/EBITDA multiple is 8.57, metrics that collectively suggest the company is valued conservatively relative to its revenue generation and enterprise value adjusted for earnings before interest, taxes, depreciation, and amortization. Over the past year, the stock has exhibited extreme volatility, with a 52-week high of $19.70 and a 52-week low of $1.64. Without the current share price explicitly provided in the source data, the valuation context is strictly defined by this wide trading range, highlighting the significant price swings inherent in small-cap healthcare stocks. The beta value is 9.37, which signifies that the stock's price volatility is substantially higher than the broader market, making it highly sensitive to market fluctuations and sector-specific news.
Growth & Income
Revenue growth year-over-year has declined by 16.5%, while earnings growth year-over-year has contracted by 32.0%, indicating that profitability is deteriorating at a faster rate than the top line. This divergence implies that the company is facing increasing cost pressures or margin compression that are outpacing any decline in sales volume, leading to a sharper reduction in net income. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute any portion of its earnings to shareholders. Instead, the company retains all of its net income, which can be directed toward reducing the negative free cash flow or funding research and development for new medical aids. The overall growth and income profile reflects a challenging period characterized by double-digit contraction in both revenue and earnings, with no income generated through dividends and significant cash outflows impacting liquidity.